유바이오로직스
Financials
Valuation Metrics
유바이오로직스's Market Cap is ₩3065B. At end of 2025 it was ₩4175B. Ranked #614 of 2,436 in KR market (top 25%), #245 of 1,649 on KOSDAQ (top 15%), #70 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 306.51B KRW | KR#614/2,436 Sec#70/234 |
| Revenue | 125.33B KRW | KR#1,269/2,436 Sec#78/234 |
| Net Income | 29.23B KRW | KR#517/2,436 Sec#36/234 |
| Total Assets | 235.16B KRW | KR#1,167/2,436 Sec#82/234 |
| Net Assets | 179.72B KRW | KR#989/2,436 Sec#71/234 |
| Employees | 353 | KR#683/2,436 Sec#60/234 |
| Value | ||
| P/E | 10.49x | KR#745/2,436 Sec#38/234 |
| P/B | 1.71x | KR#1,872/2,436 Sec#134/234 |
| P/S | 2.45x | KR#1,927/2,436 Sec#113/234 |
| EV/EBITDA | 6.21x | KR#313/2,436 Sec#9/234 |
| FCF Yield | 14.22% | KR#472/2,436 Sec#13/234 |
| Profitability | ||
| ROE | 16.27% | KR#199/2,436 Sec#13/234 |
| ROA | 12.43% | KR#121/2,436 Sec#12/234 |
| Op. Margin | 36.66% | KR#28/2,436 Sec#7/234 |
| Revenue Growth | -60.41% | KR#2,311/2,436 Sec#205/234 |
| Earnings Growth | -76.66% | KR#1,302/2,436 Sec#87/234 |
| Financial Health | ||
| Debt Ratio | 130.85% | KR#872/2,436 Sec#101/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 43.57B KRW | KR#329/2,436 Sec#19/234 |
| Cash | 21.31B KRW | KR#1,206/2,436 Sec#89/234 |
| Current Ratio | 3.99x | KR#417/2,436 Sec#72/234 |
| Net Debt/EBITDA | -0.46x | KR#593/2,436 Sec#35/234 |
| Performance | ||
| 1Y Return | -32.58% | KR#1,632/2,436 Sec#141/234 |
| 1M Return | -4.25% | KR#1,324/2,436 Sec#134/234 |
| From 52W High | -52.88% | KR#1,335/2,436 Sec#112/234 |
| 1Y MDD | -54.38% | KR#1,125/2,436 Sec#90/234 |
| Trading | ||
| Volume | 109,967 shares | KR#885/2,436 Sec#89/234 |
| Foreign Own. | 7.28% | KR#612/2,436 Sec#57/234 |
| Per Share | ||
| EPS | 798 KRW | KR#723/2,436 Sec#52/234 |
| BPS | 4,894 KRW | KR#1,460/2,436 Sec#108/234 |
Company Info
Established in 2010 and listed on KOSDAQ in 2017, this company is a specialized venture in vaccine manufacturing and biopharmaceutical contract research and manufacturing. It operates vaccine businesses, supplying 'Euvichol-S' to UNICEF and others, and provides biopharmaceutical CRMO services, with first and second factories and a research institute in Chuncheon. By expanding its cholera vaccine facilities, the company has established an annual production system of up to 90 million doses. It aims to become a global vaccine company through the development of diverse vaccine pipelines. Eubiologics is headquartered in Gangnam-gu, Seoul Special City.